Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A cDNA clone (GOR47-1) bearing an epitope with an aminoacid sequence GRRGQKAKSNPNRPL (GOR epitope) was isolated from the plasma of a laboratory chimpanzee infected with human non-A, non-B hepatitis (NANBH) agent. The epitope was not encoded by reported sequences of hepatitis C virus (HCV) but instead was coded for by a host cellular sequence. An enzyme-linked immunosorbent assay (ELISA) was developed for antibodies to the GOR epitope (anti-GOR). A patient with acute NANBH produced both IgM and IgG classes of anti-GOR in the acute phase of the illness, with concentrations of IgG class anti-GOR rising when anti-HCV became detectable. Anti-GOR was detected in serum from 59 (81%) of 73 patients with chronic NANBH, 40 (65%) of 62 with NANB liver cirrhosis, and 25 (63%) of 40 NANB patients with primary hepatocellular carcinoma, but in only less than 10% of patients with chronic liver diseases due to hepatitis B virus, alcohol, or an autoimmune disorder, and in only 2% of voluntary blood donors. Circulating HCV-RNA was detected by polymerase chain reaction (PCR) in most patients seropositive for anti-GOR but negative for anti-HCV. Detection of anti-GOR would therefore help in the diagnosis of NANBH and in reducing the occurrence of post-transfusion hepatitis.
 ...
PMID:Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process. 167 Jun 64

HCV infection frequently leads to liver cirrhosis and the development of hepatocellular carcinoma, while the mechanisms of carcinogenesis are still unclear. Autoantibodies like antinuclear antibodies have been described to increase and change their specificity in patients with hepatocellular carcinoma. Autoantibodies against GOR, an antigen not encoded by the viral but by the host's genome and overexpressed in tumor cells, are frequently associated with hepatitis C infection, but their significance during the development of hepatocellular carcinoma has not been determined yet. We analysed the frequency of GOR-antibodies in 38 patients with hepatocellular carcinoma on the grounds of liver cirrhosis of different origin, 38 patients with extrahepatic tumors, 24 patients with hepatitis C infection and 30 healthy controls. GOR-antibodies were found to be specifically associated with hepatitis C and were only found in patients with hepatocellular carcinoma if the liver cirrhosis was due to HCV-infection. Patients with extrahepatic tumors with or without liver metastasis had no detectable GOR antibodies, if no HCV infection was present. The determination of antibodies to the autoantigen GOR therefore has no clinical significance in patients with hepatic or extrahepatic tumors not related to HCV infection.
 ...
PMID:GOR-antibodies in patients with chronic liver disease and hepatocellular carcinoma. 797 76

We present 10 Italian patients with type 2b autoimmune hepatitis (anti-LKMI positivity) and HCV infection. 6 patients had IgG concentrations above the upper limit of normal and all had histological features of chronic autoimmune hepatitis or chronic persistent hepatitis or cirrhosis. ANA and SMA were positive in 2 patients, pANCA in 3 patients. Anti-GOR were negative in all patients, 6 of them were HLA B8 DR3 and 2 HLA B8 DR4. Antibodies to HCV (tested by ELISA 2nd and 3rd generation) were positive in all patients and in 9 subjects were detected HCV RNA. The two patients with positivity for ANA and SMA were treated successfully with corticosteroids, but they relapsed after the drug withdrawal; the others received interferon, that had to be suspended in 2 patients because inducing an autoimmune thyroiditis. Although, at present, it is still not known if HCV is a really trigger factor in developing autoimmunity or if the two diseases are coincidental, the authors suggest that it is important for clinicians to use appropriate treatment strategies on the basis of the predominant illness.
 ...
PMID:Type 2 autoimmune hepatitis and hepatitis C viraemia. 876 75